Comparative Pharmacology
Head-to-head clinical analysis: IMITREX STATDOSE versus ZECUITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMITREX STATDOSE versus ZECUITY.
IMITREX STATDOSE vs ZECUITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective agonist at serotonin 5-HT1B/1D receptors, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission.
Selegiline is a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B). It inhibits the breakdown of dopamine by MAO-B, increasing dopaminergic activity in the brain.
6 mg subcutaneously once, may repeat after 1 hour if needed; maximum 12 mg in 24 hours.
Apply one 1.3 mg/24 hour transdermal system to a clean, dry, hairless area of the upper arm or thigh for 24 hours; can be repeated at 24-hour intervals for up to 12 weeks.
None Documented
None Documented
Terminal half-life ~2 hours; clinical context: no significant accumulation with repeated dosing.
The terminal elimination half-life of sumatriptan is approximately 2 hours (range 1–4 hours). Due to this short half-life, a second dose may be considered if migraine recurs after initial relief, but no more than two doses in 24 hours via the same route.
Approximately 60% renal, 40% fecal (via bile); <1% unchanged in urine.
Sumatriptan is primarily eliminated by metabolism followed by renal excretion of metabolites. Approximately 60% of a dose is recovered in urine (22% as unchanged sumatriptan, 38% as metabolites) and 40% in feces (primarily metabolites).
Category C
Category C
Triptan
Triptan